NetScientific PLC ProAxsis Achieves CE Mark for Plasmin Immunoassay (1658B)
08 January 2018 - 6:00PM
UK Regulatory
TIDMNSCI
RNS Number : 1658B
NetScientific PLC
08 January 2018
NetScientific plc
("NetScientific" or the "Company" or the "Group")
ProAxsis Achieves CE Mark and Launches its ProteaseTag(R) Active
Plasmin Immunoassay
London, UK - January 8(th) 2018 - NetScientific plc
("NetScientific", AIM:NSCI), the transatlantic healthcare IP
commercialisation group, provides an update on its portfolio
company ProAxsis, which today announces that it has successfully
registered a CE Mark for its ProteaseTag(R) Active Plasmin
Immunoassay, which has potential application in a broad range of
disease indications including lung disorders.
The Active Plasmin Immunoassay is the first CE-Marked test to
enable the specific measurement of the active form of plasmin, the
target protease which is widely believed to be involved in the
pathogenesis of lung disorders such as idiopathic pulmonary
fibrosis (IPF) and acute respiratory distress syndrome (ARDS).
Commenting on the news, Francois Martelet, Chief Executive
Officer of NetScientific and Chairman of ProAxsis, said: "We are
pleased to announce that ProAxsis has registered a third product
with a CE Mark, as it continues to commercialise its growing
portfolio of novel protease-targeting point-of-care tests. We are
also particularly pleased to announce the first product launch with
applications in both respiratory health and other disease states
including pre-eclampsia, nephrotic syndrome and diabetes
mellitus."
NetScientific holds a 57% stake on a fully diluted basis in
ProAxsis.
The full text of the announcement from ProAxsis can be found
below.
# # #
For more information, please contact:
NetScientific Tel: +44 (0)20 3514 1800
François R. Martelet,
M.D., CEO
Ian Postlethwaite,
CFO
Consilium Strategic
Communications Tel: +44 (0)20 3709 5700
Mary-Jane Elliott / netscientific@consilium-comms.com
Jessica Hodgson /
Chris Welsh / Laura
Thornton
Stifel Nicolaus Europe Tel: +44 (0) 20 7710 7600
Limited (NOMAD and Broker)
Jonathan Senior / David
Arch / Ben Maddison
ProAxsis Launches ProteaseTag(R) Active Plasmin Immunoassay
following CE Mark registration
Date: January 8th, 2018
ProAxsis Limited (www.proaxsis.com) today announces that it has
successfully registered a CE Mark for its ProteaseTag(R) Active
Plasmin Immunoassay. This novel technology will enable academic and
pharmaceutical researchers to specifically measure only the active
form of plasmin, a protease associated with fibrinolysis. It is
believed that plasmin is involved in the pathogenesis of lung
disorders such as idiopathic pulmonary fibrosis (IPF) and acute
respiratory distress syndrome (ARDS). Plasmin activity is also
dysregulated in several other disease states, including
pre-eclampsia, nephrotic syndrome and diabetes mellitus. The
registration of a CE Mark indicates that the ProteaseTag(R) Active
Plasmin Immunoassay complies with EU legislation, and the company
will immediately commercialise the Immunoassay through its existing
network of respiratory contacts across Europe.
Commenting on the news, Dr David Ribeiro, CEO of ProAxsis, said:
"This is the third product for which ProAxsis has been able to
register a CE Mark, and we're delighted to add the ProteaseTag(R)
Active Plasmin Immunoassay to our existing portfolio of products.
As well as being a useful research tool, Plasmin continues to
interest pharmaceutical companies as a potential therapeutic target
in a range of different diseases. We expect to present data on this
new assay at a major respiratory conference in the second half of
the year, and look forward to expanding our range of products to
enable the measurement of the active form of additional proteases
during 2018."
Any queries concerning ProAxsis' Immunoassay for measuring
active plasmin, or any requests for support with measuring other
active protease biomarkers using the Company's proprietary
ProteaseTag(R) technology, can be directed to
info@proaxsis.com.
About NetScientific
NetScientific is a transatlantic healthcare technology group
with an investment strategy focused on sourcing, funding and
commercialising technologies that significantly improve the health
and well-being of people with chronic diseases. For more
information, please visit the website at www.netscientific.net
About ProAxsis Limited
ProAxsis is developing a range of products for the capture,
detection and measurement of active protease biomarkers of
diseases. Its first immunoassay measures active neutrophil
elastase, a leading indicator of infection and inflammation in
patients with Cystic Fibrosis (CF), Chronic Obstructive Pulmonary
Disease (COPD) and bronchiectasis, and an important drug target. A
rapid point-of-care test for measuring neutrophil elastase, called
NEATstik(R), was registered with a CE Mark in September 2017. The
laboratory-based immunoassays and point-of-care tests being
developed by ProAxsis incorporate patented ProteaseTags(R); smart
molecules which trap an active protease within a complex biological
sample and enable a visual readout of its presence. ProteaseTags(R)
provide a unique tool to identify and quantify active protease
biomarkers and will assist in the clinical validation of new
therapeutics.
ProAxsis is part of the NetScientific Group and is one of the
Group's core portfolio companies. The company is also supported by
QUBIS, the commercialisation arm of Queens University.
This information is provided by RNS
The company news service from the London Stock Exchange
END
PFUDDGDBSBGBGIR
(END) Dow Jones Newswires
January 08, 2018 02:00 ET (07:00 GMT)
Netscientific (LSE:NSCI)
Historical Stock Chart
From Apr 2024 to May 2024
Netscientific (LSE:NSCI)
Historical Stock Chart
From May 2023 to May 2024